Document is current
Any future updates will be listed below
-
Authors
Mehta, Anita K.
Cheney, Emily M.
Hartl, Christina A.
Pantelidou, Constantia https://orcid.org/0000-0003-2750-9352
Oliwa, Madisson
Castrillon, Jessica A.
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Hurst, Katie E.
de Oliveira Taveira, Mateus https://orcid.org/0000-0001-8091-6593
Johnson, Nathan T. https://orcid.org/0000-0002-2952-6730
Oldham, William M. https://orcid.org/0000-0003-3029-4866
Kalocsay, Marian https://orcid.org/0000-0002-4187-5829
Berberich, Matthew J.
Boswell, Sarah A. https://orcid.org/0000-0002-3118-3378
Kothari, Aditi
Johnson, Shawn
Dillon, Deborah A.
Lipschitz, Mikel
Rodig, Scott
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Garber, Judy E.
Tung, Nadine
Yélamos, José
Thaxton, Jessica E.
Mittendorf, Elizabeth A.
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Shapiro, Geoffrey I.
Guerriero, Jennifer L. https://orcid.org/0000-0002-2104-5457
- License Information
-
More Information
Article History
Received: 7 October 2019
Accepted: 27 October 2020
First Online: 14 December 2020
Competing interests
: J.L.G. is a consultant for GlaxoSmithKline (GSK), Codagenix, Verseau, Kymera and Array BioPharma and receives sponsored research support from GSK, Array BioPharma and Eli Lilly. G.I.S. has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros and Zentalis and has received sponsored research support from Merck, Eli Lilly, Merck/EMD Serono and Sierra Oncology. Clinical trial support from Pfizer and Array Biopharma was provided to the DFCI for the conduct of investigator-initiated studies led by G.I.S. He holds a patent entitled, ‘Dosage regimen for sapacitabine and seliciclib’, also issued to Cyclacel Pharmaceuticals and a pending patent entitled ‘Compositions and methods for predicting response and resistance to CDK4/6 inhibition’, together with L. Cornell. E.A.M. is on the scientific advisory board (SAB) for AstraZeneca/MedImmune, Celgene, Genentech, Genomic Health, Merck, Peregrine Pharmaceuticals, SELLAS Life Sciences and TapImmune and has clinical trial support for her former institution (MDACC) from AstraZeneca/MedImmune, EMD Serono, Galena Biopharma and Genentech, as well as Genentech support from an SU2C grant, as well as sponsored research support for the laboratory from GSK and Eli Lilly. S.R. receives research funding from Merck, Bristol Myers Squibb, Gilead and Affimed and is on the SAB for Immunitas. S.S. is a consultant for RareCyte, Inc. N.T. receives research support from AstraZeneca. P.K.S. serves on the SAB or board of directors of Glencoe Software, Applied BioMath and RareCyte, Inc. and has equity in these companies; he is a member of the NanoString SAB and is also a co-founder of Glencoe Software, which contributes to and supports the open-source OME/OMERO image informatics software used in this paper. D.A.D. consults for Novartis and is on the advisory board for Oncology Analytics, Inc. S.J. receives consulting fees from Venn Therapeutics.
